<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515641</url>
  </required_header>
  <id_info>
    <org_study_id>8591-030</org_study_id>
    <secondary_id>MK-8591-030</secondary_id>
    <nct_id>NCT04515641</nct_id>
  </id_info>
  <brief_title>Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Participants With Moderate Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose study of the plasma pharmacokinetics (PK), safety, and&#xD;
      tolerability of islatravir (ISL, MK-8591), and the intracellular PK of ISL triphosphate&#xD;
      (ISL-TP) in male and female adult participants with moderate hepatic impairment and in&#xD;
      healthy matched control participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Actual">September 13, 2021</completion_date>
  <primary_completion_date type="Actual">September 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve from Dosing to Infinity (AUC0-∞) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The AUC0-∞ of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Dosing to Last Measurable Concentration (AUC0-last) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The AUC0-last of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The Cmax of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The Tmax of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-Life (t½) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The t½ of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance of (CL/F) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The CL/F of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL in Plasma</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours postdose</time_frame>
    <description>The Vz/F of ISL in plasma will be determined in each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥1 Adverse Event (AE)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The percentage of participants experiencing an AE will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Treatment due to AE(s)</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>The percentage of participants discontinuing study therapy due to AE(s) will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)</measure>
    <time_frame>Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours postdose</time_frame>
    <description>The intracellular AUC0-∞ of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last of ISL-TP in PBMCs</measure>
    <time_frame>Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours postdose</time_frame>
    <description>The intracellular AUC0-last of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ISL-TP in PBMCs</measure>
    <time_frame>Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours postdose</time_frame>
    <description>The intracellular Cmax of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration 24 Hours Postdose (C24) of ISL-TP in PBMCs</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>The intracellular C24 of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration 168 Hours Postdose (C168) of ISL-TP in PBMCs</measure>
    <time_frame>168 hours postdose</time_frame>
    <description>The intracellular C168 of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration 672 Hours Postdose (C672) of ISL-TP in PBMCs</measure>
    <time_frame>672 hours postdose</time_frame>
    <description>The intracellular C672 of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ISL-TP in PBMCs</measure>
    <time_frame>Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours postdose</time_frame>
    <description>The intracellular Tmax of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of ISL-TP in PBMCs</measure>
    <time_frame>Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours postdose</time_frame>
    <description>The intracellular t½ of ISL-TP in PBMCs will be determined in each arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Human Immunodeficiency Virus (HIV) Infection</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of ISL 60 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of ISL 60 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>Two ISL 30 mg capsules taken by mouth.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Control Participants:&#xD;
&#xD;
          -  Is in good health based on medical history, physical examination, vital sign (VS)&#xD;
             measurements and electrocardiograms (ECGs) performed prior to randomization&#xD;
&#xD;
          -  Is in good health based on laboratory safety tests obtained at the screening visit and&#xD;
             prior to administration of the initial dose of study drug.&#xD;
&#xD;
          -  Has a body mass index (BMI) ≥18.5 and ≤40 kg/m2&#xD;
&#xD;
        Hepatic Impairment Participants:&#xD;
&#xD;
          -  Has a diagnosis of chronic (&gt; 6 months), stable (no acute episodes of illness within&#xD;
             the previous 2 months due to deterioration in hepatic function) hepatic insufficiency&#xD;
             with features of cirrhosis due to any etiology&#xD;
&#xD;
          -  Has a score on the Child-Pugh scale ranging from 7 to 9 (moderate hepatic&#xD;
             insufficiency) at screening&#xD;
&#xD;
          -  With the exception of hepatic impairment, is in generally good health&#xD;
&#xD;
          -  Has a BMI ≥ 18.5 and ≤ 40 kg/m2&#xD;
&#xD;
        Healthy and Hepatic Impairment Participants:&#xD;
&#xD;
          -  Males : uses contraception according to local regulations&#xD;
&#xD;
          -  Females: is not pregnant or breastfeeding and one of the following applies:&#xD;
&#xD;
          -  Is not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
          -  Is a WOCBP and uses an acceptable contraceptive method&#xD;
&#xD;
          -  A WOCBP with negative highly sensitive pregnancy test within 24 hours of study&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major&#xD;
             neurological (including stroke and chronic seizures) abnormalities or diseases&#xD;
&#xD;
          -  Is mentally or legally incapacitated, has significant emotional problems at the time&#xD;
             of prestudy (screening) visit or expected during the conduct of the study or has a&#xD;
             history of clinically significant psychiatric disorder of the last 5 years&#xD;
&#xD;
          -  Has a history of cancer (malignancy)&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies, or has had an&#xD;
             anaphylactic reaction or significant intolerability (ie, systemic allergic reaction)&#xD;
             to prescription or non-prescription drugs or food&#xD;
&#xD;
          -  Has known hypersensitivity to the active substance or any of the excipients of the&#xD;
             study drug&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, HIV-1 or HIV-2&#xD;
&#xD;
          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the prestudy (screening) visit&#xD;
&#xD;
          -  Is unable to refrain from or anticipates the use of any medication, including&#xD;
             prescription and nonprescription drugs or herbal remedies beginning approximately 2&#xD;
             weeks (or 5 half-lives) prior to study drug administration, throughout the study,&#xD;
             until the poststudy visit&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks (or 5 half-lives,&#xD;
             whichever is greater) prior to the prestudy (screening) visit&#xD;
&#xD;
          -  Has a QTc interval &gt;470 for males or &gt;480 ms for females, has a history of risk&#xD;
             factors for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of&#xD;
             long QT syndrome), has uncorrected hypokalemia or hypomagnesemia, is taking&#xD;
             concomitant medications that prolong the QT/QTc interval&#xD;
&#xD;
          -  Is not considered low risk of having HIV infection&#xD;
&#xD;
          -  Is a smoker or user of electronic cigarettes and/or has used nicotine or&#xD;
             nicotine-containing products (eg, nicotine patch) within 3 months of screening&#xD;
&#xD;
          -  Consumes greater than 3 glasses of alcoholic beverages per day&#xD;
&#xD;
          -  Consumes more than 6 caffeinated beverages per day&#xD;
&#xD;
          -  Is a regular user of illicit drugs or has a history of drug abuse within 2 years&#xD;
&#xD;
          -  Presents any concern to the investigator regarding safe study participation&#xD;
&#xD;
          -  Is unwilling to comply with study restrictions&#xD;
&#xD;
          -  Is or has an immediate family member who is investigational site or Sponsor staff&#xD;
             directly involved with this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami ( Site 0001)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

